Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MASP2 | O00187 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222446 | 1.00 | RXFP1 (0.55) | RXFP1KMT2AMASP2POLBKDM4E | |
| SCHEMBL30173444 | 0.87 | KMT2A (0.54) | RXFP1KMT2AMASP2POLBKDM4E | |
| SCHEMBL1690938 | 0.87 | KMT2A (0.54) | RXFP1KMT2AMASP2POLBKDM4E | |
| SCHEMBL29992092 | 0.87 | RXFP1 (0.59) | RXFP1KMT2APOLBLMNAMEN1 | |
| SCHEMBL15368377 | 0.87 | RXFP1 (0.59) | RXFP1KMT2APOLBLMNAMEN1 | |
| SCHEMBL29663621 | 0.87 | RXFP1 (0.55) | RXFP1KMT2APOLBKDM4ELMNA | |
| SCHEMBL5812852 | 0.86 | KDM4E (0.51) | RXFP1KMT2APOLBKDM4ELMNA | |
| SCHEMBL3248129 | 0.86 | NPC1 (0.54) | RXFP1KMT2AKDM4ELMNAMEN1 | |
| SCHEMBL2703465 | 0.86 | ALDH1A1 (0.54) | RXFP1KMT2APOLBLMNABRD9 | |
| SCHEMBL2880191 | 0.86 | LMNA (0.54) | RXFP1KMT2APOLBCA12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852326-A | PROTAC compound for targeted degradation of PI3K 110 beta and preparation method and application thereof | 河南大学 | 2024-10-29 | — | — | CN | claimed |
| CN-122102960-A | Synthesis method of nafamostat mesylate | — | 2026-05-29 | — | — | CN | disclosed |
| CN-121913953-A | Preparation method of nafamostat mesylate | 鲁南制药集团股份有限公司 | 2026-04-24 | — | — | CN | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| CN-116253720-B | Pomalidomide linked urea feed additive and preparation method and application thereof | 河南湾流生物科技有限公司 | 2025-09-16 | — | — | CN | disclosed |
| CN-117327052-B | 1,2, 3-Triazole feed additive as well as preparation method and application thereof | 河南湾流生物科技有限公司 | 2025-09-16 | — | — | CN | disclosed |
| WO-2025081045-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20240358735-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-10-31 | — | — | US | disclosed |
| CN-118852326-A | PROTAC compound for targeted degradation of PI3K 110 beta and preparation method and application thereof | 河南大学 | 2024-10-29 | — | — | CN | disclosed |
| EP-4444300-A2 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4392037-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | Boyce Thompson Institute for Plant Research Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-111867549-B | Methods and kits for glycan analysis using blocked 2-AA | 安捷伦科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117327052-A | 1,2, 3-triazole feed additive as well as preparation method and application thereof | 河南湾流生物科技有限公司 | 2024-01-02 | — | — | CN | disclosed |
| WO-2023107696-A2 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-116253720-A | Pomalidomide linked urea feed additive and preparation method and application thereof | 河南湾流生物科技有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023028350-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-113200885-B | Anthranilamide compound based on vorinostat framework, and preparation and application thereof | 南华大学 | 2023-01-06 | — | — | CN | disclosed |
| CN-113185454-B | Anthranilic acid amide compound based on entinostat skeleton and preparation and application thereof | 南华大学 | 2022-07-05 | — | — | CN | disclosed |
| US-11376200-B2 | Methods and kits for using blocked 2-AA for glycan analysis | AGILENT TECHNOLOGIES, INC. | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358735-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | MAG, PMP22, B3GAT3 | RXFP1 4165/4885KMT2A 3775/4885MASP2 183/4885 |
| US-11376200-B2 | Methods and kits for using blocked 2-AA for glycan analysis | FUT5, FUT6, B3GNT2 | RXFP1 3662/4885KMT2A 649/4885MASP2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.